• 8 April 2013
  • Features
  • By Vipul

Top 10 Bioscience collaborations in 2012

India has recognized that its strength lie in generics, clinical research and vaccine space and the players of these spaces have swiftly moved to collaborate with some of the renowned names of the industry to diversify their footprints globally


As the market for new drugs evolves, the methodologies for moving them into the market is changing and becoming more complex. Companies are increasingly relying on efficient-collaboration strategies between various parties involved in the entire value chain.

With the dawning of personalized medicine and the passing era of blockbuster molecules, pharmaceutical companies are slowly transforming from an industry of products to one of information. In addition, the shift to more integrated global operations, and a distributed organizational structure, make the reliance on effective collaboration tools of paramount importance. In today's rapidly evolving pharma market, firms are relying on efficient collaboration strategies in order to counter.

BioSpectrum looks at the top 10 collaborative developments that happened in the bioscience industry in India during 2012.

Biocon-Bristol-Myers Squibb (BMS)
Biocon has a long standing relationship with BMS for drug discovery and development and a dedicated discovery and development center employing over 400 scientists at the Biocon Park in Bangalore. Biocon recently extended this relationship further by partnering with BMS for global development of its novel molecule oral insulin. Biocon will progress further on global development pathways with the support from BMS expertise in taking molecules from lab to market. Dr Kiran Mazumder-Shaw, chairman and managing director, Biocon pointed out,

"The purpose of this partnership is to accelerate the progress of this novel molecule through global clinical trials under guidance from a well entrenched global player, in order to meet the unmet needs of diabetic patients across the world. Biocon's oral insulin will possibly be the first oral insulin of the world to hit the market. We are confident that with BMS' expertise available to Biocon, we will be able to take oral insulin forward on its development pathway much faster. We look forward to working closely with BMS to shape our dream into reality."

Previous 1 3 4 5 6 7 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

BusinessWire India.com - Healthcare & biotechnology


Research Unveiled: Pigmentary Skin Disorders & Premature Hair Greying Most

Wednesday, 18 Jan 2017   |   L’Oréal India Pvt. Ltd.

Business Wire IndiaResearch conducted by recipients of the IADVL-L’Oréal Indian Skin & Hair research

BusinessWire India.com - Pharmaceutical


'The Pediatric Network' Launches TPN Mobile App

Friday, 20 Jan 2017   |   The Pediatric Network

Business Wire IndiaThe Pediatric Network is an alternate child health support program, aimed to simplify

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA

Thursday, 19 Jan 2017   |   Boehringer Ingelheim

Business Wire India Boehringer Ingelheim announced that BI 695501, its adalimumab biosimilar candidate

BusinessWire India.com - Medical Devices


Bioventus Selects MEDSERVICE to Distribute DUROLANE® in Russia

Wednesday, 18 Jan 2017   |   Bioventus

Business Wire India Bioventus, a leader in orthobiologic solutions, announced it has selected MEDSERVICE

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email